Cell-depleting agents assessment in preclinical models

BRGSF-HIS & hFcγR to assess cell depletion

November 3, 2023

Depletion of undesirable immune cells has shown to be a promising approach to treat cancer. B-cell-depleting antibodies such as rituximab are often used to treat patients with lymphoma and was shown to improve patients’ survival. Cell depletion can be triggered by antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC). ADCP and ADCC activities are mediated by Fcγ receptors (FcγR) expressed on immune cells such as natural killer (NK) and macrophages. Translatable assessment of cell-depleting agents in preclinical models requires the presence of functional immune cells and expression of FcγR receptors. Importantly, FcγR expression in mouse and human are distinct, thus increasing the complexity of depleting antibodies assessment studies in preclinical models. Herein, we described two preclinical humanized models for assessment of cell-depleting agents.

Related products

Catalogue product

BRGSF-HIS

BRGSF-HIS mice possess the most functional reconstituted human immune system currently on the market and are highly relevant for translational research.

Customized product

No items found.

Related posters

BRGSF-HIS mice as a predictive tool for safety assessment of biologics

BRGSF-HIS for safety assessment

(Charles River) Validation of humanized PD-1 knock-in mice as an emerging model to evaluate human specific PD-1 therapeutics

hPD-1 mice as a model to evaluate human specific PD-1 therapeutics

(Charles River) Enhanced anti-tumor lymphocyte function and frequencies measured by multichromatic flow cytometry in human CTLA-4 knock-in mice in a colorectal carcinoma model after treatment with ipilimumab

hCTLA-4 mice as a colorectal carcinoma model

(Kineta) A Fully Human anti-VISTA Antibody as a Promising Therapy Against Poorly Immunogenic Tumors

anti-hVISTA against poorly immunogenic tumors

(Arcus) AB598, a Therapeutic Anti-Human CD39 Antibody, Binds and Inhibits CD39 Enzymatic Activity In Vivo to Promote Anti-Tumor Immunity

Anti hCD39 to promote anti-tumor immunity

(Sensei) SNS-101, a monoclonal antibody that is highly selective for VISTA in the tumor microenvironment, demonstrates favorable pharmacokinetic and cytokine release characteristics and potentiates anti-PD-1 responsiveness

VISTA in the tumor microenvironment

(Curadev) Intravenous administration of the small molecule STING agonist CRD5500 elicits potent anti-tumor immune responses in cold tumors

hSTING & anti-tumor response in cold tumors

(AstraZeneca) AZD5863: a specific, potent, affinity-optimized Claudin 18.2 and CD3 binding T cell-engager that elicits low cytokine release and is capable of bystander killing

CD3 binding T-cell engagement

(Anaveon) ANV600 is a novel PD-1 targeted IL-2Rβ/γ agonist that is combinable with therapeutic PD-1 inhibitors

Novel PD-1 targeted IL-2Rβ/γ agonist

(VIB) A Cross-Species Map and Humanized Mouse Model of Fcγ Receptors and FcRn

Humanized Mouse Model of Fcγ Receptors

(Reaction Biology) Humanized PD-1 knock-in mice as a model system for combination therapies with human specific PD-1 therapeutics

hPD-1 to evaluate novel cancer therapies

(Anaveon) ANV600 is a potent, cis-signaling, IL-2Rβ/γ directed IL-2 which efficiently expands intratumoral stem-like CD8 T cells

PD-1 & strong tumor growth inhibition

(Maxivax) Sustained delivery of low-dose anti-CTLA-4 by genetically engineered encapsulated cells drives tumor response and prolongs survival in a colorectal cancer model

CTLA-4 & survival in a colorectal cancer model

(Macomics) Discovery of MACO355: a first in mechanism ligand-blocking independent LILRB1/2/3 antibody for cancer therapy

In vivo tumor growth suppression

(Sensei) Conditionally active CD28xVISTA bispecific antibodies induce myeloid-driven tumor-specific T-cell co-stimulation for improved cancer immunotherapy

CD28xVISTA bispecific antibodies in immunotherapy

(Bonum) A Novel Method for Generating Regulated Cytokine Therapeutics: Safety and Activity of a Conditionally Active cLAG3-IL2 Capable of Delivering IL-2 to LAG-3+ Cells While Remaining Inert on LAG-3- Cells

Safety and activity of a conditionally active cLAG3-IL2

(Cidara) Discovery of a multispecific CD73/PD-1 targeting Drug Fc-Conjugate (DFC), which improves tumor reduction compared to PD-1 monotherapy in a humanized mouse model

Multispecific CD73/PD-1 targeting

Novel FcγR humanized mouse models enabling efficacy and PK/PD of therapeutic antibodies

FcγR mouse models for efficacy and PK/PD

Tumor cell line-derived xenograft subtype shapes tumor microenvironment composition in BRGSF-HIS mice

BRGSF-HIS & tumor microenvironment

Functional human myeloid cells in BRGSF-HIS humanized mice enable myeloid-directed therapy assessment

BRGSF-HIS for myeloid-directed therapy assessment

Myeloid cells' contribution is key in CRS pathophysiology induced by T-cell engagers in BRGSF-HIS model

BRGSF-HIS & myeloid cell compartment in CRS

Translatable preclinical mouse models for assessment of T-cell engager-induced CRS

BRGSF-HIS & CD3ε in CRS

CD3 humanized mouse models as validated tools to assess immune-related adverse events of T-cell engagers

CD3 and BRGSF-HIS to assess IrAEs

Anti-VISTA agents profiling: complementarity of BRGSF-HIS and hVISTA Knock-in as preclinical models for immunotherapies

BRGSF-HIS & hVISTA for immunotherapies

Show all posters

Humanized targets